ADMA Biologics, Inc. (ADMA) Financials
ADMA Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 684.2 million | 276.0 million |
| March 31, 2026 | 665.2 million | 274.9 million |
| Dec. 31, 2025 | 624.2 million | 146.9 million |
| Sept. 30, 2025 | 568.7 million | 137.5 million |
ADMA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | 27.3 million | 6.1 million |
| March 31, 2026 | 55.7 million | 6.3 million |
| Dec. 31, 2025 | 34.6 million | 5.4 million |
| Sept. 30, 2025 | -1.1 million | 5.0 million |
ADMA Net Income
No data available :(
ADMA Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 136.0 million | 192.8 million | 7.3 million |
| March 31, 2026 | 138.2 million | 193.6 million | 7.5 million |
| Dec. 31, 2025 | 87.6 million | 69.3 million | 7.7 million |
| Sept. 30, 2025 | 61.4 million | 70.1 million | 10.7 million |
ADMA Shares Outstanding
ADMA Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 2.3 million | 6.0 million | 26.7 million | - |
| March 31, 2026 | 2.5 million | 2.6 million | 26.7 million | - |
| Dec. 31, 2025 | 1.1 million | 1.4 million | 23.5 million | - |
| Sept. 30, 2025 | 14.4 million | 1.5 million | 23.0 million | - |
ADMA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 124.4 million | 38.1 million |
| March 31, 2026 | 114.5 million | 33.7 million |
| Dec. 31, 2025 | 139.2 million | 50.3 million |
| Sept. 30, 2025 | 134.2 million | 58.6 million |
ADMA Revenue by Segment
Graph available only for paid members. Upgrade to see it.
ADMA
Price: $9.47
52 week price:
Earnings Per Share: 0.70 USD
P/E Ratio: 14.15
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 2.7 million
Ebitda: -13.6 millionMarket Capitalization: 2.2 billion